Answer
Yes, immune-mediated nephritis has been reported in patients receiving pembrolizumab (Keytruda), and patients should be monitored for changes in kidney function, with other causes of kidney dysfunction excluded.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 67Document updated
Sources checked